依达拉奉对体外循环心脏手术患者心肌缺血再灌注损伤治疗作用的meta分析

摘要

Aim: To assess the effectiveness of edaravone for treatment against ischemic-reperfusion injury (IRI) in patients undergoing cardie operation with cardiopulmonary by-pass. Methods: The related articles were searched, Pubmed, Highwire Press, EMBASE, WAN FANG DATA.CNKI and China Biological Medcine Database from Apr. 2001 to Jul. 2010.The Revman 5.0 software was used for the meta analysis. ReSUltS:A total of 6 RCT (n =202) were identified. The level of methodology was classified as B. Compared with the control group,in edravone group,there are significant difference in the spontaneous return rates of hearts after aorta declamping was higher (RR = 1.54,95% C/= 1.05 -2.25.P =0.03) ; and also in plasma concentration of MDA( at 2 h,6 h and 24 h after aorta declamping) ,serum concentation of SOD(24 h after surgery operation 95% CI = 0. 47 ~ 1. 18, SMD = 0. 82, P < 0. 001), CK-MB and cTnl ( at 6 h and 24 h after aorta declamping). Conclusion:Edaravone may have some protective effect for the treatment against ischemic-reperfusion injuryin patients undergoing cardiac operation with cardiopulmonary by-pass.%目的：运用meta分析法评价依达拉奉对体外循环心脏手术患者心肌缺血再灌注损伤(IRI)的疗效。方法：运用Cochrane系统评价的方法，检索Pubmed、Highwire Press、EMBASE、中国知网、万方科技文献数据库和中国生物医学文献数据库的文献及其